Updated results from the HIMALAYA Phase III trial showed AstraZeneca’s Imfinzi (durvalumab) plus Imjudo (tremelimumab) demonstrated a sustained, clinically meaningful overall survival (OS) benefit at four years for… read more.
Ipsen announced that the FDA has approved Bylvay (odevixibat) for the treatment of cholestatic pruritus in patients from 12 months of age with Alagille syndrome (ALGS). Bylvay is… read more.
Janice Couch, 62, a retired pre-school teacher from Grand Rapids, Michigan, is finally physically ready to receive two procedures that stand to change her life, thanks to Henry… read more.
A new substudy of the STEP TEENS trial presented at this year’s European Congress on Obesity (ECO 2023, Dublin 17-20 May) shows that adolescents using semaglutide experienced significant… read more.
Bariatric surgery treats advanced non-alcoholic fatty liver disease (NASH) significantly more effectively than drug or lifestyle intervention, researchers reported on April 20, 2023 in The Lancet. Professor Francesco… read more.
Metabolic (bariatric) surgery is more effective than medications and lifestyle interventions for the treatment of advanced non-alcoholic fatty liver disease. A new paper, published today in The Lancet… read more.
New research involving adults diagnosed with nonalcoholic fatty liver disease (NAFLD) and morbid obesity (body mass index > 40) indicates that subjects who had bariatric surgery achieved a… read more.
A novel artificial intelligence blood testing technology developed and used by Johns Hopkins Kimmel Cancer Center researchers to successfully detect lung cancer in a 2021 study has now… read more.
Obesity can give rise to a variety of health concerns. Nonalcoholic steatohepatitis (NASH)—a type of fatty liver disease that might progress to cancer—is particularly prevalent among obese people…. read more.
Nonalcoholic fatty liver disease (NAFLD) is the most common pediatric liver disease, affecting 5 to 8 million children in the United States. In NAFLD, the cells of the… read more.
It is estimated that about one in four adults worldwide has a liver condition that is a risk factor for heart disease, according to a new American Heart… read more.
A clinical trial conducted by researchers from RCSI University of Medicine and Health Sciences and Beaumont Hospital Dublin has indicated an effective treatment for critically ill COVID-19 patients…. read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
